The International Association for the Study of Lung Cancer (IASLC) board of directors has selected Fred R. Hirsch, MD, PhD, as the organization’s new CEO.
Dr. Hirsch will take over for the current CEO, Dr. Paul A. Bunn, Jr. MD, following the World Conference on Lung Cancer in Sydney, Australia Oct. 27-30, when Dr. Bunn’s term ends.
“Dr. Hirsch is an outstanding choice for the CEO of the IASLC and I am proud to announce that he will replace me in this role,” says Dr. Bunn.
“I was pleased to succeed Dr. Heine H. Hansen as CEO in 2003 and have been proud to serve the IASLC over the past 10 years as it matured into an important resource in thoracic cancers.
“Since Dr. Hirsch worked with both Drs. Hansen and myself and since he has served the IASLC well in many capacities, the IASLC will be well served by his selection as CEO.”
Hirsch is a professor of medicine and pathology at the CU School of Medicine in Aurora. His research interests include translational research, biomarkers and targeted therapies, and early detection of lung cancer.
Hirsch’s research has helped identify and validate prognostic markers for lung cancer outcomes and predictive markers for personalized lung cancer therapies.
He is the principle investigator on an NCI SPECS grant to establish biomarkers for squamous cell lung cancer and chairs the translational research component of the SWOG lung cancer committee.
Hirsch holds a medical degree and doctorate from the University of Copenhagen and a degree from the Copenhagen Business School. His specialty is medical oncology, but he trained in pathology as well.
Hirsch has been an active member of the IASLC since 1977.
He has served as chair of the pathology committee, chair of the prevention and early detection committee and is associate editor of the Journal of Thoracic Oncology.
He also has served on the IASLC board since 2005, and is treasurer of the association.